neuroprotection – Page 3

Oxidative Stress in Spinocerebellar Ataxia Type 3 and Its Attenuation by Herbal Remedies in Traditional Chinese Medicine: A Systematic Review

mycolabadmin

Spinocerebellar ataxia type 3 is a serious brain disease that causes movement problems and gets worse over time. Current medications help but often have unpleasant side effects. This review examined fifteen traditional Chinese herbal remedies that show promise in protecting nerve cells from damage caused by oxidative stress, a harmful chemical process in the body. These herbs work through multiple protective mechanisms and may eventually be tested in patients.

Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review

mycolabadmin

Lion’s Mane mushroom shows promising benefits for brain health, potentially improving memory and reducing symptoms of anxiety and depression. It may help prevent cancer by triggering cancer cell death and supports digestive health by promoting beneficial gut bacteria. While generally safe, some people experience mild side effects like stomach discomfort or headaches, making it an accessible supplement for overall wellness.

Hericioic Acids A–G and Hericiofuranoic Acid; Neurotrophic Agents from Cultures of the European Mushroom Hericium flagellum

mycolabadmin

Researchers isolated eight new bioactive compounds from a rare European mushroom species called Hericium flagellum. These compounds showed promising ability to stimulate nerve cell growth and could potentially help treat neurodegenerative diseases like Alzheimer’s and Parkinson’s. The study demonstrates that mushroom-derived natural products may offer new therapeutic approaches for conditions affecting millions of elderly people worldwide.

Ganoderic Acid A targeting leucine-rich repeat kinase 2 involved in Parkinson’s disease–A computational study

mycolabadmin

Researchers used computer modeling to test five compounds from Reishi mushrooms against a protein called LRRK2 that is linked to Parkinson’s disease. Ganoderic Acid A showed the strongest binding to this target protein and could potentially be developed into a treatment. The findings suggest that Reishi mushroom compounds may help protect brain cells from the degeneration seen in Parkinson’s disease and warrant further laboratory and animal testing.

Calcineurin-mediated regulation of growth-associated protein 43 is essential for neurite and synapse formation and protects against α-synuclein-induced degeneration

mycolabadmin

Researchers discovered that a specific protein called GAP-43 plays a crucial role in protecting brain cells from damage caused by α-synuclein, a protein involved in Parkinson’s Disease. When GAP-43 is modified through a process called phosphorylation at certain sites, it promotes the growth of neurites (neural connections) and formation of healthy synapses. The drug FK506, already approved by the FDA, appears to work by controlling this phosphorylation process, offering potential therapeutic benefits for Parkinson’s patients.

Optimization of Ultrasonic Extraction to Obtain Erinacine A and Polyphenols with Antioxidant Activity from the Fungal Biomass of Hericium erinaceus

mycolabadmin

Researchers developed an efficient ultrasonic extraction method to obtain beneficial compounds from the lion’s mane mushroom (Hericium erinaceus), particularly a substance called erinacine A and antioxidants. The optimized process uses 80% ethanol and takes 45 minutes, producing extracts rich in antioxidants that can protect cells from damage. These extracts showed promise in protecting brain cells and could potentially help prevent or treat neurodegenerative diseases like Alzheimer’s disease.

The Biological Activity of Ganoderma lucidum on Neurodegenerative Diseases: The Interplay between Different Active Compounds and the Pathological Hallmarks

mycolabadmin

Reishi mushroom, used in traditional Asian medicine for centuries, contains over 400 bioactive compounds that show promise in protecting the brain from degenerative diseases like Alzheimer’s and Parkinson’s. The mushroom’s components work through multiple pathways to reduce inflammation, fight oxidative stress, and protect neurons from damage. While laboratory and animal studies show encouraging results, human clinical trials are needed to confirm its effectiveness as a treatment.

Chemical Composition and In Vitro Biological Activity of the Polar and Non-Polar Fractions Obtained from the Roots of Eleutherococcus senticosus (Rupr. et Maxim.) Maxim

mycolabadmin

Siberian ginseng (Eleutherococcus senticosus) roots contain powerful antioxidant compounds that may help with inflammation, blood sugar control, and brain health. Researchers found that certain plant fractions were particularly rich in protective compounds like chlorogenic acid and caffeic acid. However, the study also discovered a concerning finding: these plant compounds protected cancer cells from chemotherapy drugs, suggesting people undergoing cancer treatment should be cautious about using this supplement.

Neuroprotective properties of anti-apoptotic BCL-2 proteins in 5xFAD mouse model of Alzheimer’s disease

mycolabadmin

Scientists studied how Bcl-2 proteins might protect the brain from Alzheimer’s disease by controlling calcium levels in nerve cells. They injected modified Bcl-2 proteins into the brains of mice engineered to develop Alzheimer’s symptoms and found that these proteins helped preserve the connections between nerve cells and reduced harmful amyloid plaque buildup. A special version of Bcl-2 that worked primarily on one type of calcium channel was surprisingly most effective at reducing amyloid plaques, suggesting this specific mechanism could be important for treating Alzheimer’s disease.

β-secretase inhibition prevents structural spine plasticity deficits in AppNL-G-F mice

mycolabadmin

Researchers tested whether a drug that blocks BACE1 (an enzyme involved in Alzheimer’s disease) could protect nerve cell connections in a mouse model of Alzheimer’s disease. They found that at high doses, the drug significantly improved the formation of new dendritic spines (connection points between neurons) and restored synaptic activity to near-normal levels. These findings suggest that using BACE1 inhibitors early in Alzheimer’s disease development, before widespread neuronal damage occurs, might help prevent cognitive decline.

Research Topic: neuroprotection